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Abstract
The Kruppel-like factor (KLF) family of transcription factors regulates diverse cell biological processes including proliferation,
differentiation, survival and growth. Previous studies have shown that KLF15 inhibits cardiac hypertrophy by repressing the
activity of pivotal cardiac transcription factors such as GATA4, MEF2 and myocardin. We set out this study to characterize
the interaction of KLF15 with putative other transcription factors. We first show that KLF15 interacts with myocardin-related
transcription factors (MRTFs) and strongly represses the transcriptional activity of MRTF-A and MRTF-B. Second, we
identified a region within the C-terminal zinc fingers of KLF15 that contains the nuclear localization signal. Third, we
investigated whether overexpression of KLF15 in the heart would have therapeutic potential. Using recombinant adeno-
associated viruses (rAAV) we have overexpressed KLF15 specifically in the mouse heart and provide the first evidence that
elevation of cardiac KLF15 levels prevents the development of cardiac hypertrophy in a model of Angiotensin II induced
hypertrophy.
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Introduction
Cardiac hypertrophy is an early hallmark and important risk
factor for the development of heart failure. Hypertrophy of
cardiomyocytes occurs in response to pathological stimuli such as
hypertension, aortic valve stenosis, myocardial infarction or
genetic mutations in sarcomeric proteins and is regarded as a
maladaptive process, since left ventricular hypertrophy (LVH)
often progresses to heart failure [1]. Cardiac hypertrophy is
accompanied by reprogramming of cardiac gene expression and
the activation of ‘fetal’ cardiac genes encoding proteins involved in
contraction, calcium handling and metabolism. Specific transcrip-
tion factors such as MEF2, GATA4, NFAT, SRF and myocardin
have been identified that activate this fetal gene program [2,3].
Besides these transcriptional factors that promote cardiac hyper-
trophy, it has also become increasingly evident that the heart
possesses a variety of endogenous feedback mechanisms to
counterbalance this growth response [4]. We and others recently
identified the transcriptional regulator KLF15 as an inhibitor of
cardiac gene expression and hypertrophy [5,6,7]. Mouse studies
showed that somatic loss of KLF15 results in increased suscepti-
bility to pressure overload-induced LVH and heart failure [6]. The
expression of KLF15 is consistently down-regulated during
pathological hypertrophy and heart failure as was shown in
animal models and patients with aortic stenosis and non-ischemic
cardiomyopathy [5,6,7]. Loss of KLF15 in the heart seems unique
for pathological hypertrophy, as KLF15 levels were not changed in
physiological hypertrophy in rats, after exercise training [7]. The
fact that KLF15 is consistently down-regulated in pathological
hypertrophy may suggest that KLF15 is not just a response to
heart failure, but that loss of KLF15 may actually contribute to the
progression of heart failure by removing transcriptional repressive
mechanisms and enabling cardiac growth [5,6,7,8]. In this regard,
it is remarkable that KLF15 is not (or at very low levels) expressed
in the developing heart, and that its expression gradually increases
after birth to reach adult levels around three weeks of age [8].
Overall, these studies indicate that overexpression of KLF15 in the
heart may provide a novel therapeutic target to counteract cardiac
hypertrophy and overt heart failure.
Mechanistically, KLF15 acts as a repressor of the cardiac
transcription factors MEF2 and GATA4 and the transcriptional
coactivator myocardin [5]. Association of KLF15 with the basic
region of myocardin has been shown to prevent binding of
myocardin to SRF, resulting in reduced expression of CArG box-
dependent genes like ANF and a-skeletal actin [7]. Two of the
family member of myocardin, Myocardin Related Transcription
Factors A and B (MRTF-A and MRTF-B) also activate SRF-
dependent transcription, to regulate expression of genes involved
in cytoskeletal organization and muscle cell differentiation. In
addition, a recent report shows that besides MYOCD, also
MRTF-A is involved in the hypertrophic response of the heart [9].
It is currently unknown whether the activity of MRTF-A and
MRTF-B is also repressed by KLF15. Besides repression of MEF2,
GATA and myocardin by KLF15, KLF15 has also been shown to
repress p300 acetyltransferase activity [6]. The observation that
p300 activity is increased in KLF15 null hearts and the recognition
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36754that p300 also acetylates GATA, MEF2 and myocardin, suggest
that the exaggerated hypertrophic response in the KLF15 null
mice is the consequence of unbridled activity of these cardiac
transcription factors [6,10].
Despite growing evidence for a role of KLF15 as a regulator of
many biological and pathological processes, only few studies have
addressed the function of the different domains within the KLF15
protein [11,12]. The only functional domain of KLF15 identified
thus far is the zinc finger region at the C-terminus, which is
required for DNA interaction [11,13].
We set out this study to characterize the interaction of KLF15
with MRTFs and found that KLF15 strongly represses the
transcriptional activity of MRTF-A and MRTF-B. Second, we
identified a region within KLF15 that contains the nuclear
localization signal. Third, we investigated if overexpression of
KLF15 in the heart has therapeutic potential for the repression of
cardiac hypertrophy. Using recombinant adeno-associated virusses
(rAAV) we have overexpressed KLF15 specifically in the mouse
heart and provide the first evidence that elevation of cardiac
KLF15 levels prevents the development of cardiac hypertrophy in
a model of Angiotensin II induced hypertrophy.
Materials and Methods
Plasmids
The ANF(638) and the SM22(505) luciferase reporter plasmids
were previously described [7]. MYOCD, MRTF-A and -B
pcDNA3.1 expression vectors were kindly provided by Dr. E. N
Olson (Dallas, USA). The KLF15 pcDNA3.1 N-FLAG expression
and PGEX-GST-wtKLF15 vector were described previously [7].
Figure 1. Cellular distribution of full-length and truncated KLF15 proteins. To determine which part of the KLF15 protein contains the
nuclear localization signal (NLS) several truncated KLF15 open reading frames were cloned into an expression vector containing an N-terminal FLAG
tag and transfected into COS-7 cells. (a) A schematic overview of the KLF15 truncated proteins. Full length murine KLF15 has a length of 416 aa and
contains three highly conserved zinc fingers (Zn1, Zn2 and Zn3) that are located at the C-terminal end of the protein (aa315-aa416). (b) COS-7 cells
transfected with the KLF15 expression plasmids were fixed and immunostainings were performed using a primary antibody against the FLAG-tag and
a fluorescent secondary antibody (Alexa 488). Nuclei were stained with DAPI. Full length KLF15 (1–416 aa) is localized in the nucleus. Truncated KLF15
proteins lacking the NLS (1–205 aa and 1–315 aa) fail to translocate to the nucleus. All KLF15 mutant proteins lacking N-terminal parts, but containing
the three zinc fingers (102–416 aa, 199–416 aa, 308–416 aa) are located in the nucleus. A KLF15 mutant lacking Zn2 and Zn3 is not located in the
nucleus indicating that both Zn2 and Zn3 are necessary for nuclear localization of KLF15. (c) To study whether the three zinc fingers of KLF15 can acts
as a NLS we fused one or more zinc fingers to eGFP. A schematic representation of the four eGFP constructs that were used are shown. (d) eGFP is
both localized in the cytosol and the nucleus. When all three zinc fingers are fused to eGFP, eGFP is restricted to the nucleus, indicating that the three
zinc fingers are sufficient to drive nuclear localization. When eGFP is only fused to Zn2 and Zn3, expression is still nuclear, but when fused to Zn3,
expression is both cytosolic and nuclear, indicating that Zn2 and Zn3 act as NLS.
doi:10.1371/journal.pone.0036754.g001
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pcDNA3.1 plasmid as a template. GFP-zinc finger fusion plasmids
were generated by cloning the GFP open reading frame lacking
the stop codon in the pcDNA3.1 vector upstream of the zinc
fingers. All plasmids were sequence verified and all primer
sequences are available upon request.
Luciferase assays
Luciferase assays were performed as previously described [7]. In
short, 75 ng of reporter plasmid, 50 ng of each expression plasmid
(unless otherwise indicated) and 30 ng of beta-galactosidase were
transfected in a 24 well plate seeded with 50.000 COS-7 cells per
well using GeneJammer as a transfectant (Stratagene). After
48 hours, cells were harvested and luciferase signals were
measured using a Glomax plate reader. Experiments were
performed in duplicate and repeated at least three times.
GST pulldown
GST-KLF15 and GST-empty plasmids were transformed into
Bl21-Gold (DE3) cells (Stratagene) and protein translation was
induced by adding 0.5 mM Isopropyl b-D-1-thiogalactopyrano-
side (IPTG). Proteins were isolated and bound to Glutathione
Sepharose 4B Beads (GE Health Care, 17-0756-01). Quality of the
GST proteins was checked by running 5 ul of protein on a 10%
SDS gel followed by staining with PageBlue
TM protein staining
solution (Fermentas). All
35S labelled proteins were translated
using a cell free TNT quick coupled translation system (Promega,
L1170) and labelled with
35S methionine (Perkin Elmer). Proteins
labelled with
35S were assayed for binding to GST-KLF15.
Cytochemical staining
TodeterminecellulardistributionoftheKLF15mutants,COS-7
cells were seeded in 24-well plates and transfected with 500 ng
expression plasmid using GeneJammer (Stratagene). Twenty-four
hours after transfection, cells were washed with PBS and fixed with
4% paraformaldehyde for 15 minutes at room temperature. Cells
werewashedwithPBSandpermeabilizedfor10 minuteswith0.1%
triton-XinPBS.AftertwoPBSwashes,cellswereincubatedat37uC
for 45 minutes with a primary antibody against the FLAG epitope
(1:250) using the anti-FLAG-M2 antibody (Stratagene). Cells were
washedwithPBSandexposedat37uCfor45 minwithanAlexa532-
conjugated goat-anti mouse antibody (1:200) (# A-11017, Invitro-
gen, Molecular probes). Nuclei were stained with DAPI.
Animal studies and AAV9 construction
The described studies are comprised within gene transfer/
therapy research of the University of Leuven, which was reviewed
and approved by the university Ethical Commission for Animal
Experimentation (file Nu P03102). Precautions were taken to
minimize animal suffering by implementing anesthesia (e.g.
Figure 2. KLF15 represses and binds MYOCD and MRTF-A and –B. (a) schematic overview of MYOCD, MRTF-A and MRTF-B. All the proteins
share a SRF binding and a (potential) KLF15 binding domain. (b) KLF15 represses MRTF-A and MRTF-B mediated activation of the SRF responsive
2505 Sm22 luciferase reporter. (c) KLF15 represses MRTF-A and MRTF-B mediated activation of the SRF responsive 2638 ANF luciferase reporter. (d)
A GST-pulldown assay using in vitro translated
35S labeled MRTF-A and MRTF-B and GST-fused KLF15 shows a direct interaction between KLF15 and
MRTF-A and –B. (e) GST pulldown assays using
35S labeled SRF and GST fused KLF15 shows no interaction between KLF15 and SRF. (f) KLF binding
site (CACCC) in the 2505 Sm22 reporter. This bindingsite is mutated to a TGTTT site. (g) deletion of the KLF binding site in the 2505 Sm22 reporter
does not affect the repressive effect of KLF15.
doi:10.1371/journal.pone.0036754.g002
Figure 3. In vivo overexpression of FLAG-KLF15 using AAV9. a) Western blot analysis of left ventricular samples revealed expression of FLAG-
KLF15 protein. b) Experimental timeline. Eight week old mice are intravenously injected with 1*10
10 vector genomic copies AAV-9 (KLF or GFP). One
week later hypertrophy is induced by implanting osmotic minipumps that release 1.5 mg/g/day of angiotensin II. Four weeks later, mice were
sacrificed.
doi:10.1371/journal.pone.0036754.g003
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36754Figure 4. Attenuation of cardiac hypertrophy in AAV9-KLF15 mice. a) Body weight is not different in sham and AngII treated animals. b)
AngII induces hypertrophy in GFP expressing mice, as measured by correcting the left ventricular weight (LVw) for body weight (Bw). This effect is
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perform to euthanasia by cervical dislocation when the experiment
was terminated.
pAAV9-cTnT-GFP and pAAV9-cTnT-FLAG-KLF15 were
derived by subcloning the open reading frame of GFP and mouse
KLF15 into pAAV-MCS (Stratagene). Subsequently, the CMV
promoter was removed by restriction and replaced by the
2374+38 chicken troponin T promoter. Virus was produced in
HEK293 cells and purified as previously described [14,15]. 10 e
10
vector genomic copies (vg) of AAV9-KLF15 and AAV9-GFP were
injected into the tail vein of eight week old male C57BL/6 mice
(n=4 in the control groups and n=5 in the AngII groups). After
one week, mini-pumps (ALZET model 2004; ALZACorp., Palo
Alto, California, USA) filled with either AngII (H-1705, Bachem)
or saline and a pumping rate of 1.5 ug/g/day were placed
subcutaneously as described earlier [16]. After 28 days, mice were
sacrificed under 2.5% isofluorane. KLF15-FLAG protein levels
were measured by Western Blotting using an anti-FLAG M2
antibody 1:500 (Stratagene) and anti-GAPDH 1:5000 (Fitzgerald
Industries International).
Histochemical Studies
Mouse hearts were fixed overnight in 4% paraformaldehyde,
dehydrated, and embedded in paraffin using standard techniques.
Consecutive 7-mm serial sections were cut and stained with
hematoxylin and azophloxine. To determine the collagen content,
deparaffinized sections were processed for Picrosirius red stain.
Cell size measurements
Cell size was determined in hematoxylin and azophloxine-
stained sections using 206magnification. To determine cell size,
we measured cross-sectional areas of ,150 individual transversely
cut cardiomyocytes using the image processing software Scion
Image. Cross-sectional areas are expressed as arbitrary units (AU).
Sirius Red quantification
Sirius red staining was quantified by using an in house made
quantification macro. Per heart/section, 160 fields were recorded
and of those 160 fields, 20 fields were randomly chosen for
quantification. Perivascular fibrosis was manually omitted from the
sections. The percentage of Sirius red positive areas in each section
was automatically calculated as a percentage of the total tissue area.
Statistical Analysis
Data are presented as mean 6 standard errors. Unpaired t test
was used to calculate p-values. P values of #0.05 were considered
statistically significant.
Results
The three zinc fingers of KLF15 are required for nuclear
localization
One requirement for a transcription factor to function is that it
has to be translocated to the nucleus. Since KLF15 lacks the
typical nuclear localization signal (NLS) PKKKRKV, KLF15
must have an alternative sequence to drive nuclear import. To
identify the region that contains the NLS of KLF15 we subcloned
several flag-tagged deletion mutants of KLF15 and overexpressed
these in COS7 cells. We performed immunostainings with an
antibody against the flag epitope to determine its cellular
localization. In Figure 1a a schematic representation can be
appreciated of the deletion mutants of KLF15 that we generated
to identify the NLS. As can be appreciated from Figure 1b,
mutants 1–205 aa and 1–315 aa, both lacking the three zinc
fingers (Zn1, Zn2 and Zn2), showed solely a cytosolic expression
pattern, which indicates that the C-terminal zinc finger region
contains the NLS. Indeed, all KLF15 mutants containing the three
zinc fingers were correctly and fully localized in the nucleus. To
further narrow down this region we used a mutant in which we
deleted the two most C-terminal zinc fingers (1–351 aa). The
protein generated from this mutant was expressed in both the
nucleus and cytosol, indicating that the region encompassing the
two most C-terminal zinc fingers is required for complete nuclear
localization (Figure 1b).
To study whether the zinc fingers are not only necessary for
nuclear localization but also sufficient to act as an NLS, we created
an expression vector containing the open reading frame of
enhanced green fluorescent protein (eGFP) fused to one or more
zinc fingers of KLF15 (Figure 1c). We transfected these plasmids
in COS-7 cells and the cellular localization was determined using
fluorescence microscopy. Naive eGFP is primarily localized in the
cytoplasm, but since it is a relatively small protein it easily
translocates to the nucleus by unspecific diffussion [17]. Fusion of
all three zinc fingers to the C-terminal end of eGFP (eGFP-Zn123)
resulted in an expression pattern that is completely restricted to the
nucleus (Figure 1d), indicating that the zinc finger region is
sufficient to act as an NLS. eGFP fused to Zn2 and Zn3 also
showed a nuclear expression whereas fusion of Zn3 only resulted
in both cytosolic and nuclear expression (Figure 2d). From these
two experiments we conclude that zinc fingers 2 and 3 are
required to translocate KLF15 to the nucleus.
KLF15 represses the activity of MRTF-A and B
We have previously shown that KLF15 physically interacts with
MYOCD resulting in a strong repression of MYOCD activity [7].
Here, we hypothesize that KLF15 represses the activity of other
SRF co-activators like MRTF-A and MRTF-B. These proteins are
family members of MYOCD and essentially contain the same
functional domains (Figure 2a) [18]. To test whether KLF15 is
able to repress the activity of MRTF-A and -B, we performed
luciferase assays using the CArG box-containing SM22 (505) and
ANF(638) reporters, which are strongly activated by myocardin,
MRTF-A and –B [19]. Co-transfection of COS7 cells with these
reporters, MRTF-A or -B and KLF15 showed that KLF15
strongly repressed MRTF-A and -B activity on both the SM22 and
the ANF reporter (Figure 2b and c). Next, we tested using GST
pulldown studies, whether KLF15 could directly interact with both
MRTFs. We used a GST-KLF15 fusion protein as a bait to test for
interaction with in vitro translated,
35S-labeled MRTF-A and –B
and show that KLF15 directly interacts with both MRTFs
(Figure 2d).
Recently, it was shown that a synergistic interaction between
KLF3 and SRF controls transcription of skeletal muscle genes
[20]. Interestingly, activation of SRF occurred via recruitment of
blunted in mice with cardiac specific overexpression of KLF15. c and d) The hypertrophic response was also measured by analysis of individual
cardiomyocyte size. Mice overexpressing KLF15 showed a blunted hypertrophic response to AngII. AU: arbitrary units. Scale bar in d represents 50 mm
e) Quantitative real-time PCR on left ventricular tissue showed an increased expression of the hypertrophic markers ANF and alpha skeletal actin
(aSKA) in GFP mice treated with angiotensin. In mice that overexpress KLF15 we found a reduction in expression of these genes, but this is not
significant. * p,0.05 compared to GFP control. # p,0.05 compared to GFP ANGII.
doi:10.1371/journal.pone.0036754.g004
KLF15 in Cardiac Hypertrophy
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e36754Figure 5. Fibrosis is attenuated by KLF15 overexpression. a) Upon induction of hypertrophy, fibrosis is increased in GFP mice. In mice
overexpressing KLF15, fibrosis seems reduced but the difference did not reach statistical significancy. b) Sirius red sections. *p,0.05 compared to
GFP control. Black scale bar represents 2 mm.
doi:10.1371/journal.pone.0036754.g005
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independent from its association to CArG boxes [20]. This finding
prompted us to examine whether KLF15 is able to physically
interact with SRF and we performed GST pulldown assays using a
GST-KLF15 fusion protein and in vitro translated
35S labeled SRF.
This revealed that there is no direct interaction between SRF and
KLF15 (Figure 2d), further underscoring that KLF15 represses
SRF-mediated transcription not by binding to SRF, but through
direct binding to MYOCD and MRTFs. Along the same lines, we
tested whether KLF15 competes with SRF for MRTF binding by
transfecting Cos cells with the Sm22-luciferase reporter and
expression vectors encoding MYOCD, MRTF-A or MRTF-B.
Luciferase assays revealed that the repression of MRTF-A and –B
by KLF15 is dose-dependent and that this repression can be
counteracted by increasing concentrations of SRF (Supplemental
Figure S2).
KLF15 represses the SM22 reporter independent of the
KLF15 binding site
Since it is currently unknown whether consensus KLF binding
sites in the promoters/enhancers of cardiac genes regulate gene
expression, we searched for KLF binding sites in promoters of
genes known to be repressed by KLF15. We noted a typical KLF
binding site (CACCC) in the promoter of SM22, 122 bp upstream
of the CArG box (Suppl Figure S1a) and several KLFs (KLF2,
3, 8 and 17) have been shown to bind this sequence [21,22,23]. To
investigate whether this KLF binding site is required for the
KLF15-mediated repression of the SM22 reporter, we mutated
this binding site (CACCC to TGTTT) (Figure 2f) and performed
luciferase assays using MYOCD to activate the wild-type (WT)
and mutated reporter. Since KLF15 similarly repressed WT and
mutated SM22 reporter (Figure 2e), we conclude that this KLF
binding site in the promoter of Sm22 is not required for the
repressive action of KL15. This provides further evidence that
KLF15 mainly represses gene transcription through interaction
with MYOCD or MRTFs.
AAV9-mediated gene transfer of KLF15 represses cardiac
hypertrophy
KLF15 is an endogenous repressor of cardiac hypertrophy, as
was evidenced by the fact that KLF15 null mice have exaggerated
cardiac hypertrophy and develop heart failure [5,6]. The fact that
KLF15 is consistently down-regulated in animal models of
hypertrophy and human heart failure may suggest that KLF15
is not a just a response to heart failure, but that loss of KLF15 may
actually contribute in the disease progression [5,6,7,8]. This
prompted us to investigate whether overexpression of KLF15 in
the heart, sufficient to prevent its down-regulation, would be able
to repress the development of hypertrophy, in a model of AngII-
induced LVH.
To increase cardiac levels of KLF15 we designed rAAV9 for
overexpression of KLF15 under the control of the 2374 chicken
cardiac troponin T promoter. This promoter has been shown to
efficiently drive the expression of SERCA in cultured rat
cardiomyocytes [24,25]. To generate a rAAV9-KLF15 construct
that is only active in the heart we subcloned the chicken cTNT
promoter upstream of FLAG-tagged KLF15 open reading frame.
As a control, we generated a cTnT-eGFP construct. Both
sequences were subcloned into a rAAV-9 vector and virus was
produced as previously described [15]. To establish AAV-9
mediated gene transfer, eight week old male C57Bl6 mice were
intravenously (i.v.) injected with 10 e
10 vector genomic copies of
rAAV9-KLF15 and rAAV9-GFP. Five weeks after injection we
assessed whether we could detect FLAG-tagged KLF15 in the
hearts of animals that were transduced with AAV9-KLF15.
Western blot analysis on cardiac tissue lysates with an antibody
directed against the FLAG epitope revealed that recombinant
KLF15 protein was efficiently produced in the hearts of AAV9-
KLF15 injected mice (Figure 3a).
To determine whether overexpression of KLF15 represses
pressure overload-induced cardiac hypertrophy, we induced
hypertrophy a week after injecting mice with the rAAV9-KLF15
and rAAV9–GFP virus, through continuous infusion of AngII
(1.5 mg/g/day) via subcutaneously placed osmotic minipumps
(Figure 3b) [16]. As can be appreciated from Figure 4a,
rAAV9-GFP infected mice develop a mild but statistically
significant increase of 25% in left ventricular weight (LVw) when
corrected for body weight (Bw) after 4 weeks of AngII infusion.
The body weights between groups are not significantly different
(Figure 4b). AngII treatment of the rAAV9-KLF15 mice resulted
in a blunted increase in LVw/Bw ratio as compared to the mice
infected with AAV9-GFP. This indicates that forced overexpres-
sion of KLF15 can inhibit the hypertrophic response of the heart.
Next, we assessed whether KLF15 overexpression affects
hypertrophic growth of individual cardiomyocytes. We measured
cross-sectional areas of ,150 individual cardiomyocytes in LV
tissue on H&E stained sections. As can be appreciated from
Figure 4c and d, the cross-sectional area of cardiomyoctyes in
the control group (rAAV9-GFP) is significantly increased (11%) in
response to AngII. In contrast, in the rAAV9-KLF15 mice this
increase in cell size was nearly abolished. We quantified the
expression of established hypertrophic marker such as atrial
natriuretic factor (ANF) and alpha skeletal actin (aSKA) using real-
time PCR on hearts and showed that the induction of these
marker genes in response to AngII treatment was slightly
attenuated in the rAAV9-KLF15 treated mice. (Figure 4e),
however this attenuation in gene expression did not reach
statistical significance.
The presence of fibrosis is another characteristic of LVH and
heart failure, and KLF15 has also been implicated in this process
[26]. We performed sirius red stainings on cardiac sections to
determine the amount of interstitial fibrosis in rAAV9-GFP and
rAAV9-KLF15 mice. As can be appreciated from Figure 5a and
b AngII infusion results in increased collagen content in AngII
treated hearts. In hearts of AAV9-KLF15 mice treated with AngII,
the increase in fibrosis is attenuated, but this difference did not
reach statistical significance.
Discussion
MYOCD is a transcriptional co-activator whose expression is
restricted to cardiomyocytes and smooth muscle cells, where it acts
as a powerful co-activator of serum response factor (SRF) and
myocyte enhancer factor 2 (MEF2), two transcription factors with
an established role in cardiac biology [27,28,29]. A recent report
shows that besides MYOCD, also MRTF-A is required for the
hypertrophic response of the heart [9]. In this study we show that
KLF15 not only binds and represses MYOCD, but also represses
the transcriptional activity of MRTF-A and MRTF-B. Although
we did not pinpoint the exact KLF15 interaction domain within
the MRTFs, it is likely that this region is similar to the one within
MYOCD, since there is high sequence homology between the
MYOCD family members, especially in the basic region (i.e. the
SRF binding region, where KLF15 is also known to bind). Since
MRTFs are expressed in a wide range of tissues, these findings
suggest roles for KLF15 in regulating SRF-dependent transcrip-
tion in other cell types and organs as well. In this regard, a recent
KLF15 in Cardiac Hypertrophy
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fibrosis in response to myocardial infarction [30]. Other reports
indicate that MRTFs and SRF play critical roles in cytoskeletal
dynamics and metastasis [31], smooth muscle biology [32] and
skeletal muscle growth [33]. A requirement for a role for KLF15 in
these processes is that KLF15 has to be expressed in these tissues.
Uchida et al. and Gray et al. showed that KLF15 is ubiquitously
expressed and that it is enriched in smooth, cardiac and skeletal
muscle as well as in the kidney and liver [8,34].
Although it is known that KLF15 is a repressor of several
transcriptional regulators, the exact mechanism by which KLF15
represses transcriptional activity remains unknown. This is largely
because of a lack of knowledge on the functional domains within
the KLF15 protein. The zinc finger region at the c-terminus of
KLF15 is the only functional domain described so far. The zinc
fingers are required for DNA binding [13], and as we have shown
in this study, also to gain entry to the nucleus. This is in agreement
with several other KLFs, where the NLS has also been identified
within the zinc finger regions [35].
During cardiac hypertrophy and heart failure, KLF15 is
consistently downregulated in patients, mice and rat models
[5,7]. Loss of KLF15 correlates with the substantial increase in
ANF and BNP expression, and the experiments in this study
provide a putative model how loss of KLF15 may contribute to
increased expression of ANF, BNP and a-skeletal actin, and
possibly other SRF- dependent target genes. In this study, we have
investigated the therapeutic potential of KLF15. We investigated
whether overexpression of KLF15 in the mouse heart is sufficient
to prevent the development of cardiac hypertrophy and fibrosis in
response to AngII-induced hypertension. Although in vitro studies
have previously revealed an inhibitory effect of KLF15 overex-
pression on cell growth, in vivo studies were lacking [5].
Efficient and long-term delivery of potential therapeutic genes
to the heart remains a major challenge for clinical implementation.
One of the most promising tools in this context are the AAVs,
which are able to take up large DNA fragments and enable stable
gene transfer to the heart [36]. Furthermore, rAAVs are non-
pathogenic, as they are replication-deficient and do not evoke an
immune response. AAV vectors have been studied for the past 30
years and these parvovirus-related viruses currently encompasses 9
serotypes [37,38]. With the discovery of different AAV serotypes
and variants it became evident that serotypes can be used to
establish an organ-specific expression of the transgene [39]. Two
recent studies showed that specifically the AAV9 serotype
efficiently transduces the heart after intravenous delivery [40,41].
This is in contrast to rAAV-1, rAAV-2 and rAAV-6 which only
slightly transduce the heart when high doses of viral genome are
injected. rAAV-8 does efficiently transduce cardiac tissue, but
relatively high virus doses are needed [36].
Swinnen et al. showed that rAAV9-mediated gene transfer is
not only very efficient, but it also has therapeutic potential for
heart disease. When they overexpressed thrombospondin-2 (TSP-
2) using AAV9-CMV-TSP vectors in the hearts of TSP-2 null
mice they were able to rescue accelerated age-induced cardiomy-
opathy completely [15]. In 2009, Jaski et al. performed a human
phase 1/2 clinical trial using rAAV1 to overexpress SERCA2a in 9
patients with advanced heart failure [42]. This study did not raise
any safety concerns. Even though the study cohort was too small to
conduct statistical analysis, some patients showed improvements in
LV function (ejection fraction and end systolic volume), biomark-
ers (NT-proBNP) and function (walking test and VO2 max). The
above described findings emphasize that AAV mediated gene
therapy is a potentially efficient and successful way to overexpress
therapeutic targets, however further clinical evaluation is war-
ranted.
Specificity of gene transfer to cardiomyocytes can be increased
by incorporating a cardiac promoter, instead of the CMV
promoter into the AAV9 vector [37,43]. In the current study,
but also in the study of Prasad et al., the chicken cardiac troponin
T (cTnT) 2374+43 promoter was introduced in the rAAV9 vector
[36]. This promoter has been shown to efficiently drive transgene
expression in cardiomyocytes [24,25] and Prasad et al. provided
evidence that the cTnT-rAAV9-eGFP vector efficiently transduces
the heart (up to 96% of cardiac cells) resulting in high eGFP
expression levels. In the current study, we have used western blot
analysis to demonstrate that cTnT-rAAV9-KLF15 transduction
results in the generation of KLF15 protein in the heart.
Previous work of Wang et al. showed that KLF15 also has a
functioninthecardiacfibroblast,whereitrepressestheexpressionof
thepro-fibroticcytokineCTGF[16,26]andinhibitsECMsynthesis.
Overall, excessive deposition of ECM is a negative hallmark of
cardiac remodeling since it stiffens the heart thereby hindering
proper contraction. Mice lacking KLF15 are not only sensitized to
the development of hypertrophy and heart failure, but they also
develop severe fibrosis [26]. In the AAV9-KLF-15 treated mice, we
did not find a statistically significant inhibition on the development
of fibrosis, which may be explained by the fact that we did not
overexpress KLF15 in the fibroblast but in the cardiomyocyte
However, since CTGF is also expressed and secreted by cardiomy-
ocytes (especially in the stressed heart), it could very well be possible
that the mechanism of CTGF repression by KLF15 is shared by the
myocytes of the heart [44][26].
In conclusion, the fact that cardiomyocyte-specific KLF15
overexpression may reduce cardiomyocyte hypertrophy seems
beneficial and suggests that KLF15 may be used as a therapeutic
target for hypertrophy and heart failure. Future studies are
warranted to establish whether overexpression of KLF15 improves
cardiac function and whether it can also prevent hypertrophy in
more severe models of hypertrophy and heart failure, such as
transverse aortic constriction.
Supporting Information
Figure S1 Sequence of the 2505 sm22 and 2423+98
hBNP reporters. The Sm22 and BNP reporters contain several
conserved transcription factor binding sites: CArG-box (yellow),
GATA (blue), KLF (red).
(TIF)
Figure S2 KLF15 competes with SRF for MRTF inter-
action. Cos cells were transfected with Sm22 luciferase and
expression vectors encoding myoardin (panel A), MRTF-A (panel
B) or MRTF-B (panel C) and increasing concentrations of KLF15
and SRF as indicated. Luciferase activity is expressed as fold
change over the empty expression vector pcDNA3.1. 50 indicates
that 50 ng was transfected to a well of a 24-well plate. Increasing
concentrations indicated by the triangle range from 1 to 50 ng.
(TIF)
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